Anna Billeschou

Ms. Anna Billeschou


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2022 in Communications Biology
Verified
Journal Article
Open access
PDF file
ABAnna Billeschou
Anna Billeschou
CJChristian Dall Johansen
Christian Dall Johansen
JCJens Bager Christensen
Jens Bager Christensen
SKSasha Alexandra Sampson Kjeldsen
Sasha Alexandra Sampson Kjeldsen
KGKatrine Douglas Galsgaard
Katrine Douglas Galsgaard
NANicolai Wewer Albrechtsen
Nicolai Wewer Albrechtsen
Glucagon is a major regulator of metabolism and drugs targeting the glucagon receptor (GCGR) are being developed. Insight into tissue and cell-specific expression of the GCGR is important to understand the biology of glucagon and to differentiate between direct and indirect actions of glucagon. However, it has been challenging to localize the GCGR in tissue due to low expression levels and lack of specific methods. Immunohistochemistry has frequently been used for GCGR localization, but antibodies targeting G-protein-coupled-receptors may be inaccurate. We evaluated all currently commercially available GCGR antibodies. The antibody, ab75240 (Antibody no. 11) was found to perform best among the twelve antibodies tested and using this antibody we found expression of the GCGR in the kidney, liver, preadipocytes, pancreas, and heart. Three antibody-independent approaches all confirmed the presence of the GCGR within the pancreas, liver and the kidneys. GCGR expression should be evaluated by both antibody and antibody-independent approaches.

7 January 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
ABAnna Billeschou
Anna Billeschou
JHJenna Hunt
Jenna Hunt
AGAruna Ghimire
Aruna Ghimire
Jens HolstJens Holst
Jens Holst
HKHannelouise Kissow
Hannelouise Kissow
Intestinal adaptation is an important response and a natural repair mechanism in acute intestinal injury and is critical for recovery. Glucagon-like peptide 2 (GLP-2) has been demonstrated to enhance mucosal repair following intestinal damage. In this study, we aimed to investigate the role of GLP-2 receptor activation on intestinal protection and adaptation upon chemotherapy-induced intestinal injury. The injury was induced with a single injection of 5-fluorouracil in female GLP-2 receptor knockout (GLP-2R(-/-)) mice and their wild type (WT) littermates. The mice were euthanized in the acute or the recovery phase of the injury; the small intestines were analysed for weight changes, morphology, histology, inflammation, apoptosis and proliferation. In the acute phase, only inflammation was slightly increased in the GLP-2R(-/-) mice compared to WT. In the recovery phase, we observed the natural compensatory response with an increase in small intestinal weight, crypt depth and villus height in WT mice, and this was absent in the GLP-2R(-/-) mice. Both genotypes responded with hyperproliferation. From this, we concluded that GLP-2R signalling does not have a major impact on acute intestinal injury but is pivotal for the adaptive response in the small intestine.

1 November 2024 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Open access
ABAnna Billeschou
Anna Billeschou
CJChristian Dall Johansen
Christian Dall Johansen
KGkatrine Galsgaard
katrine Galsgaard
EEEmilie Elmelund
Emilie Elmelund
MWMarie Winther-Sørensen
Marie Winther-Sørensen
CSCharlotte M. Sørensen
Charlotte M. Sørensen
This study suggests that the glucagon receptor is a potential therapeutic target in the treatment of diabetic kidney disease. We show, in mice, that long-term treatment with a glucagon analog showed not only pathophysiological changes and changes in renal function but also transcriptional changes in the kidneys, whereas opposite effects were demonstrated in mice with glucagon receptor inactivation. Therefore, the use of glucagon in a treatment regimen requires investigation of possible metabolic and renal abnormalities.

23 December 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
ABAnna Billeschou
Anna Billeschou
CJChristian Dall Johansen
Christian Dall Johansen
SKSasha Kjeldsen
Sasha Kjeldsen
KGkatrine Galsgaard
katrine Galsgaard
JCJens Bager Christensen
Jens Bager Christensen
NANicolai Wewer Albrechtsen
Nicolai Wewer Albrechtsen
Glucagon is a key regulator of numerous metabolic functions including glucose, protein and lipid metabolism, and glucagon-based therapies are explored for diabetes, fatty liver disease and obesity. Insight into tissue and cell specific expression of the glucagon receptor (GCGR) is important to understand the biology of glucagon as well as to differentiate between direct and indirect actions of glucagon. However, it has been challenging to accurately localize the GCGR in tissue due to low expression levels and lack of specific methodologies. Immunohistochemistry has frequently been used for GCGR localization, but G-protein-coupled receptors (GPCRs) targeting antibodies are notoriously unreliable. In this study, we systematically evaluated all commercially available GCGR antibodies. Initially, twelve GCGR antibodies were evaluated using HEK293 cells transfected with mouse or human GCGR cDNA. Of the twelve antibodies tested, eleven showed positive staining of GCGR protein from both species. Human liver tissue was investigated using the same GCGR antibodies. Five antibodies failed to stain human liver biopsies (despite explicit claims to the contrary from the vendors). Immunohistochemical (IHC) staining demonstrated positive staining of liver tissue from glucagon receptor knockout ( Gcgr −/− ) mice and their wild-type littermates ( Gcgr +/+ ) with only one out of the twelve available GCGR antibodies. Three antibodies were selected for further evaluation by western blotting and bands corresponding to the predicted size of the GCGR (62 kDa) were identified using two of these. Finally, a single antibody (no. 11) was selected for specific GCGR localization studies in various tissues. In mouse tissue the most intense immunostainings were found in lever, kidney, ileum, heart, and pancreas. Western blotting, performed on liver tissue from Gcgr +/+ and Gcgr −/− mice, confirmed the specificity of antibody no. 11, detecting a band at high intensity in material from Gcgr +/+ and no bands in liver tissue from Gcgr −/− mice. Staining of human kidney tissue, with antibody no. 11, showed GCGR localization to the distal tubules. Autoradiography was used as an antibody-independent approach to support the antibody-based findings, revealing specific binding in liver, pancreas, and kidney. As a final approach, RNA-sequencing and single-cell RNA (scRNA)-sequencing were implemented. RNA-sequencing confirmed GCGR presence within liver and kidney tissue. The GCGR was specifically found to be expressed in hepatocytes by scRNA-sequencing and potentially also in collecting and distal tubule cells in the kidney. Our results clearly indicate the liver and the kidneys as the primary targets of glucagon action.

1 October 2026 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Open access
ABAnna Billeschou
Anna Billeschou
MWMarie Winther-Sørensen
Marie Winther-Sørensen
NANicolai Wewer Albrechtsen
Nicolai Wewer Albrechtsen
Jens HolstJens Holst
Jens Holst
CSCharlotte M. Sørensen
Charlotte M. Sørensen
Glucagon is best known for raising blood sugar, but what does it do to the kidneys? We show that glucagon consistently drives sodium and water excretion in rats through a direct tubular mechanism, largely independent of changes in renal blood flow. Neither glucagon receptor nor GLP-1 receptor blockade alone was sufficient to abolish the response, revealing overlapping receptor pathways. These findings have implications for the growing use of glucagon-based dual and triple agonist therapies.